Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27779398 | 0.83 | MGLL (0.35) | MGLLPHGDHKMT2ALMNAMAPT | |
| SCHEMBL3316476 | 0.79 | MGLL (0.38) | MGLLPHGDHKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL1044396 | 0.77 | TACR3 (0.34) | KMT2ALMNATDP1 | |
| SCHEMBL3318020 | 0.75 | MGLL (0.34) | MGLLPHGDH | |
| SCHEMBL12747180 | 0.71 | EPHX2 (0.43) | SMN1; SMN2TDP1 | |
| SCHEMBL3317239 | 0.71 | ALDH1A1 (0.32) | KMT2ALMNATDP1 | |
| SCHEMBL12474755 | 0.70 | LMNA (0.42) | MGLLPHGDHLMNAMAPTTDP1 | |
| SCHEMBL25335914 | 0.70 | TACR3 (0.39) | KMT2ALMNATDP1 | |
| SCHEMBL2352547 | 0.70 | TACR3 (0.39) | KMT2ALMNATDP1 | |
| SCHEMBL3317695 | 0.68 | EPHX2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105727-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF | DONG-A-PHARM. CO., LTD. (KR) | 2010-04-29 | — | — | US | disclosed |
| EP-2137152-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Dong-A Pharm.Co., Ltd. (KR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008114971-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | DONG-A PHARM. CO., LTD. (KR) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105727-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF | HTR4, HTR1A, TPH1 | MGLL 2171/4885PHGDH 2219/4885KMT2A 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.